Development of In Situ Self-Assembly Nanoparticles to Encapsulate Lopinavir and Ritonavir for Long-Acting Subcutaneous Injection

Most antiretroviral medications for human immunodeficiency virus treatment and prevention require high levels of patient adherence, such that medications need to be administered daily without missing doses. Here, a long-acting subcutaneous injection of lopinavir (LPV) in combination with ritonavir (...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaudommongkon, Irin, Tanaudommongkon, Asama, Dong, Xiaowei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235542/
https://www.ncbi.nlm.nih.gov/pubmed/34207272
http://dx.doi.org/10.3390/pharmaceutics13060904

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235542/
https://www.ncbi.nlm.nih.gov/pubmed/34207272
http://dx.doi.org/10.3390/pharmaceutics13060904

Ejemplares similares